2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2618

Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Abstract Number: 2852

Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women
Abstract Number: 2191

Widespread Regulation of Gene Expression By Glucocorticoids in Chondrocytes from OA Patients As Determined By NGS-Based Genome Wide Expression Analysis
Abstract Number: 2929

WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β
Abstract Number: 2388

Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Abstract Number: 2237

Work Productivity and Activity Impairment in Primary Sjögren’s Syndrome
Abstract Number: 363

Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Abstract Number: 590

X-Ray Spine Lesions Are Rare and Not Discriminant for Axial Spondyloarthritis Recognition in Patients with Recent Onset Chronic Back Pain
Abstract Number: 155

Xerostomia in Patients with Fibromyalgia
Abstract Number: 2243

Youtube Videos on Rheumatoid Arthritis: A Qualitative Analysis of Views and Content
Abstract Number: 1412

Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 325

Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Abstract Number: 37

β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].